Guobang Pharma Ltd. (605507.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 17.40

From 52W high−47.42%

Volume18.05M

Market capCNY 12.03B

P/E (TTM)14.7x

P/S (TTM)2.3x

Div yield3.30%

Key dataSep 18, 2026

Open

CNY 17.40

From 52W high

−47.42%

Volume

18.05M

Market cap

CNY 12.03B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.2x

P/E (TTM)

14.7x

RSI (14)

71.1

MomentumView details →

1D Return

−1.28%

YTD Return

−26.73%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

14.7x

EV/EBITDA

9.2x

EV/Sales

2.2x

P/S (TTM)

2.3x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

25.19%

Net Margin

12.58%

EBITDA Margin

23.67%

ROE (TTM)

8.80%

ROA (TTM)

6.73%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+1.67%

EPS YoY

−3.19%

FCF YoY

+671.63%

Revenue CAGR 3Y

+1.66%

EPS CAGR 3Y

−3.56%

EBITDA YoY

—

MomentumView details →

1D Return

−1.28%

YTD Return

−26.73%

1Y Return

−19.39%

RSI (14)

71.1

vs 50D SMA

+14.19%

vs 200D SMA

−15.11%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

2.54x

Quick Ratio

1.86x

Div Yield

3.30%

Div Rate

CNY 0.60

Div Growth 1Y

+38.65%

EarningsView details →

EPS (Actual)

CNY 0.24

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

6.09B

Net Income (TTM)

766.47M

Op. CF (TTM)

1.10B

Latest newsMore news →

Guobang Pharma's wholly owned subsidiary Zhejiang Guobang Pharmaceutical received an 'A' status from China's CDE for its injectable-grade glyceryl dipalmitate excipient, clearing it for commercial supply to downstream formulation customers.5d ago

Similar companies

浙江医药600216.SH Sunshine Lake Pharma Co., Ltd.06887.HK Ab&B Bio Tech Co Ltd.02627.HK 健友股份603707.SH 微芯生物688321.SH XD国药现600420.SH Find similar companies →

Latest newsMore news →

Guobang Pharma's wholly owned subsidiary Zhejiang Guobang Pharmaceutical received an 'A' status from China's CDE for its injectable-grade glyceryl dipalmitate excipient, clearing it for commercial supply to downstream formulation customers.5d ago